jhv1blz5 wrote: The article validated SOA as an IT architecture paradigm that can be leveraged in many ways. Taking data storage, scalability and application performance to a nifty level using SOA Application Grid infrastructure will no doubt enhance data and application performance on Oracle architecture platforms, it also has the promise of a cost effective and efficient IT delivery model. The very benefits of SOA.
PRINCETON, NJ -- (MARKET WIRE) -- 04/05/07 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a
pharmaceutical company that develops and markets dermatology products,
today announced that Dr. Geert Cauwenbergh, Chief Executive Officer, will
participate in the CIBC World Markets Annual Biotechnology and Specialty
Pharmaceuticals Conference.
The conference will be held at the Millennium Broadway Hotel in New York,
NY on April 11 - April 12, 2007. Barrier Therapeutics is scheduled to
present on Thursday, April 12, at 9:10 a.m. EDT (6:10 a.m. PDT).
The presentation will be available via a live webcast and can be accessed
through the Investor Relations section of Barrier Therapeutics' corporate
website at: www.barriertherapeutics.com. An archive of the presentation
will be available for replay for 90 days.
About Barrier Therapeutics
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the
development and commercialization of products in the field of dermatology.
Barrier Therapeutics currently markets three pharmaceutical products in the
United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, for seborrheic
dermatitis; Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35%
white petrolatum) Ointment, for diaper dermatitis complicated by documented
candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical
Solution, for solar lentigines. Barrier Therapeutics has other product
candidates in various stages of clinical development for the treatment of a
range of dermatological conditions, including onychomycosis, psoriasis,
acne, skin allergies, and acute fungal infections. The company is
headquartered in Princeton, New Jersey and has wholly owned subsidiaries in
Geel, Belgium and Ontario, Canada. More information about Barrier
Therapeutics can be found on its corporate website at:
www.barriertherapeutics.com.
Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.
Contact:
Barrier Therapeutics, Inc.
Anne M. VanLent
EVP & CFO
(609) 945-1202